Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 9/20 | 0.42 |
| ▸ | DRD3 | P35462 | 6/20 | 0.42 |
| ▸ | DRD4 | P21917 | 4/20 | 0.42 |
| ▸ | DRD1 | P21728 | 2/20 | 0.42 |
| ▸ | DRD5 | P21918 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | HTR1D | P28221 | 2/20 | 0.39 |
| ▸ | HTR5A | P47898 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30665126 | 1.00 | DRD2 (0.42) | DRD2DRD3DRD4DRD1DRD5 | |
| Hydrogen Sulfide SCHEMBL28795253 | 0.98 | DRD2 (0.41) | DRD2DRD3DRD4DRD1DRD5 | |
| Biphenyl SCHEMBL4350539 | 0.93 | DRD2 (0.39) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL23301867 | 0.87 | DRD2 (0.40) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL3240871 | 0.86 | DRD2 (0.36) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL1712875 | 0.86 | DRD2 (0.43) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL6934553 | 0.85 | MAPT (0.43) | DRD2DRD3DRD4DRD1DRD5 | |
| Hydrogen Sulfide SCHEMBL27838727 | 0.84 | MAPT (0.42) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL10029309 | 0.83 | DRD2 (0.41) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL19948194 | 0.82 | DRD2 (0.41) | DRD2DRD3DRD4DRD1DRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115368494-A | Hexafluoroisopropanol-containing monomer copolymer, preparation method thereof, chemical amplification type photoresist and application | 瑞红(苏州)电子化学品股份有限公司 | 2022-11-22 | — | — | CN | claimed |
| CN-110903316-B | Phosphonate compound and preparation method and application thereof | 中南大学 | 2021-03-02 | — | — | CN | claimed |
| CN-110903316-A | Phosphonate compound and preparation method and application thereof | 中南大学 | 2020-03-24 | — | — | CN | claimed |
| EP-3004120-B1 | SPIRO-1,1'-BIINDANE-7,7-BISPHOSPHINE OXIDES AS HIGHLY ACTIVE SUPPORTING LIGANDS FOR PALLADIUM-CATALYZED ASYMMETRIC HECK REACTION | UNIV NANYANG TECH (SG) | 2018-08-29 | — | — | EP | claimed |
| US-20160136629-A1 | SPIRO-1,1'-BINDANE-7,7-BISPHOSPHINE OXIDES AS HIGHLY ACTIVE SUPPORTING LIGANDS FOR PALADIUM-CATALYZED ASYMMETRIC HECK REACTION | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2016-05-19 | — | — | US | claimed |
| US-12100809-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-09-24 | — | — | US | disclosed |
| CN-116023383-A | Synthesis method of chiral tetrahydrofurano [2,3-b ] tetrahydroquinoline derivative | 广西师范大学 | 2023-04-28 | — | — | CN | disclosed |
| CN-114650988-A | Fluorinated quinoline and quinoxaline derivatives as inhibitors of dihydroorotate dehydrogenase (DHODH) for the treatment of cancer, autoimmune and inflammatory diseases | 詹森生物科技公司 | 2022-06-21 | — | — | CN | disclosed |
| US-20220149436-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2022-05-12 | — | — | US | disclosed |
| US-11283107-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2022-03-22 | — | — | US | disclosed |
| US-11220475-B2 | Monomers from biomass | NDSU RESEARCH FOUNDATION (US) | 2022-01-11 | — | — | US | disclosed |
| CN-113692401-A | Process for producing aromatic amino acid derivative | 中外制药株式会社 | 2021-11-23 | — | — | CN | disclosed |
| EP-1167372-A1 | 2,2-(Diaryl)vinylphosphine compound, palladium catalyst thereof, and process for producing arylamine, diaryl, or arylalkyne with the catalyst | Takasago International Corporation (JP) | 2002-01-02 | — | — | EP | disclosed |
| US-RE36256-E | ADMINISTERING ARYL-SUBSTITUTED QUINOXALINE DERIVATIVES AS ANTIPROLIFERATIVE, ANTICARCINOGENIC AND ANTITUMOR AGENTS | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1999-07-20 | — | — | US | disclosed |
| US-5817877-A | Metal-catalyzed amination of organic sulfonates to organic amines | YALE UNIVERSITY (US) | 1998-10-06 | — | — | US | disclosed |
| US-5795889-A | INHIBITING CELL GROWTH WITH ENZYME INHIBITORS FOR SKIN DISORDERS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-08-18 | — | — | US | disclosed |
| US-5656643-A | QUINOLIN PYRIDINE DERIVATIVES; USEFUL FOR TREATING CANCER, LEKEMIA, PSORIASIS, INFLAMMATORY DISODERS, BONE DISORDERS, ATHEROSCLEROSIS AND RESTENOSIS; CONTROLLS CELLULAR REPRODUCTION | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-08-12 | — | — | US | disclosed |
| US-5646153-A | INHIBITING ABNORMAL CELL PROLIFERATION | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-07-08 | — | — | US | disclosed |
| US-5480883-A | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1996-01-02 | — | — | US | disclosed |
| US-5409930-A | Inhibits abnoramal cell proliferation; dimethoxyquinoline/ dimethylquinoline/ quinolineoxide/ and quinoxaline derivatives | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1995-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160136629-A1 | SPIRO-1,1'-BINDANE-7,7-BISPHOSPHINE OXIDES AS HIGHLY ACTIVE SUPPORTING LIGANDS FOR PALADIUM-CATALYZED ASYMMETRIC HECK REACTION | SBK1, SIK1, PDPK1 | DRD2 1852/4885DRD3 1765/4885DRD4 1059/4885 |
| US-11220475-B2 | Monomers from biomass | DCXR, MGAM, ALG1 | DRD2 3654/4885DRD3 3850/4885DRD4 3169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.